San Diego, CA -- (SBWIRE) -- 04/05/2017 -- A deadline is coming up on April 7, 2017 in the lawsuit filed for certain investors of Aratana Therapeutics Inc (NASDAQ:PETX) over alleged securities laws violations by Aratana Therapeutics Inc .

Investors who purchased shares of Aratana Therapeutics Inc (NASDAQ:PETX) have certain options and there are strict and short deadlines running. Deadline: April 7, 2017.. NASDAQ:PETX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of certain purchasers of Aratana Therapeutics Inc (NASDAQ:PETX) that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 16, 2015 and February 3, 2017 the Defendants made false and/or misleading statements and/or failed to disclose that Aratana Therapeutics Inc did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale, that consequently, ENTYCE was not likely to be commercially available until late 2017, that accordingly, Aratana Therapeutics Inc had misled investors with respect to the likely timeline for a commercial launch of ENTYCE, and that as a result of the foregoing, Aratana Therapeutics Inc's public statements were materially false and misleading at all relevant times.

On February 6, 2017, Aratana Therapeutics Inc disclosed that the Center for Veterinary Medicine ("CVM") had requested more information about the Company's appetite stimulation drug ENTYCE. Aratana Therapeutics Inc advised investors that it "now anticipates that ENTYCE . . . will be commercially available by late 2017" and that the CVM's request was "in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale."

Those who purchased shares of Aratana Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com